Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
BEIGENE NZ UNLIMITED,Zanubrutinib,"Relapsed or refractory Chronic lymphocyticÂ leukemia (CLL) or Small lymphocytic lymphoma (SLL) , 17p deletion or TP53 mutation disease, second line",Zanubrutinib (BRUKINSA),Only if cost neutral or cost saving,Community and Hospital,
